IBDEI06T ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,2668,2)
 ;;=^5003745
 ;;^UTILITY(U,$J,358.3,2669,0)
 ;;=L02.91^^7^83^9
 ;;^UTILITY(U,$J,358.3,2669,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2669,1,3,0)
 ;;=3^Abscess, skin and soft tissue
 ;;^UTILITY(U,$J,358.3,2669,1,4,0)
 ;;=4^L02.91
 ;;^UTILITY(U,$J,358.3,2669,2)
 ;;=^5009016
 ;;^UTILITY(U,$J,358.3,2670,0)
 ;;=L02.818^^7^83^3
 ;;^UTILITY(U,$J,358.3,2670,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2670,1,3,0)
 ;;=3^Abscess, cutaneous of other sites
 ;;^UTILITY(U,$J,358.3,2670,1,4,0)
 ;;=4^L02.818
 ;;^UTILITY(U,$J,358.3,2670,2)
 ;;=^5009011
 ;;^UTILITY(U,$J,358.3,2671,0)
 ;;=B20.^^7^83^11
 ;;^UTILITY(U,$J,358.3,2671,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2671,1,3,0)
 ;;=3^Acquired Immunodeficiency Syndrome (AIDS)
 ;;^UTILITY(U,$J,358.3,2671,1,4,0)
 ;;=4^B20.
 ;;^UTILITY(U,$J,358.3,2671,2)
 ;;=^5000555
 ;;^UTILITY(U,$J,358.3,2672,0)
 ;;=B44.1^^7^83^17
 ;;^UTILITY(U,$J,358.3,2672,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2672,1,3,0)
 ;;=3^Aspergillosis,Pulmonary
 ;;^UTILITY(U,$J,358.3,2672,1,4,0)
 ;;=4^B44.1
 ;;^UTILITY(U,$J,358.3,2672,2)
 ;;=^5000664
 ;;^UTILITY(U,$J,358.3,2673,0)
 ;;=B44.89^^7^83^16
 ;;^UTILITY(U,$J,358.3,2673,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2673,1,3,0)
 ;;=3^Aspergillosis NEC
 ;;^UTILITY(U,$J,358.3,2673,1,4,0)
 ;;=4^B44.89
 ;;^UTILITY(U,$J,358.3,2673,2)
 ;;=^5000667
 ;;^UTILITY(U,$J,358.3,2674,0)
 ;;=R78.81^^7^83^19
 ;;^UTILITY(U,$J,358.3,2674,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2674,1,3,0)
 ;;=3^Bacteremia
 ;;^UTILITY(U,$J,358.3,2674,1,4,0)
 ;;=4^R78.81
 ;;^UTILITY(U,$J,358.3,2674,2)
 ;;=^12280
 ;;^UTILITY(U,$J,358.3,2675,0)
 ;;=T80.219A^^7^83^20
 ;;^UTILITY(U,$J,358.3,2675,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2675,1,3,0)
 ;;=3^Bacteremia, associated w/ central venous cath, init encntr
 ;;^UTILITY(U,$J,358.3,2675,1,4,0)
 ;;=4^T80.219A
 ;;^UTILITY(U,$J,358.3,2675,2)
 ;;=^5054359
 ;;^UTILITY(U,$J,358.3,2676,0)
 ;;=B40.2^^7^83^22
 ;;^UTILITY(U,$J,358.3,2676,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2676,1,3,0)
 ;;=3^Blastomycosis,Pulmonary
 ;;^UTILITY(U,$J,358.3,2676,1,4,0)
 ;;=4^B40.2
 ;;^UTILITY(U,$J,358.3,2676,2)
 ;;=^5000641
 ;;^UTILITY(U,$J,358.3,2677,0)
 ;;=B40.3^^7^83^23
 ;;^UTILITY(U,$J,358.3,2677,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2677,1,3,0)
 ;;=3^Blastomycosis,Skin and soft tissue
 ;;^UTILITY(U,$J,358.3,2677,1,4,0)
 ;;=4^B40.3
 ;;^UTILITY(U,$J,358.3,2677,2)
 ;;=^5000642
 ;;^UTILITY(U,$J,358.3,2678,0)
 ;;=B40.89^^7^83^21
 ;;^UTILITY(U,$J,358.3,2678,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2678,1,3,0)
 ;;=3^Blastomycosis NEC
 ;;^UTILITY(U,$J,358.3,2678,1,4,0)
 ;;=4^B40.89
 ;;^UTILITY(U,$J,358.3,2678,2)
 ;;=^5000645
 ;;^UTILITY(U,$J,358.3,2679,0)
 ;;=J20.9^^7^83^25
 ;;^UTILITY(U,$J,358.3,2679,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2679,1,3,0)
 ;;=3^Bronchitis, Acute
 ;;^UTILITY(U,$J,358.3,2679,1,4,0)
 ;;=4^J20.9
 ;;^UTILITY(U,$J,358.3,2679,2)
 ;;=^5008195
 ;;^UTILITY(U,$J,358.3,2680,0)
 ;;=B37.42^^7^83^26
 ;;^UTILITY(U,$J,358.3,2680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2680,1,3,0)
 ;;=3^Candidal Balanitis
 ;;^UTILITY(U,$J,358.3,2680,1,4,0)
 ;;=4^B37.42
 ;;^UTILITY(U,$J,358.3,2680,2)
 ;;=^5000617
 ;;^UTILITY(U,$J,358.3,2681,0)
 ;;=B37.3^^7^83^33
 ;;^UTILITY(U,$J,358.3,2681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2681,1,3,0)
 ;;=3^Candidiasis,Vulvovaginal
 ;;^UTILITY(U,$J,358.3,2681,1,4,0)
 ;;=4^B37.3
 ;;^UTILITY(U,$J,358.3,2681,2)
 ;;=^5000615
 ;;^UTILITY(U,$J,358.3,2682,0)
 ;;=B37.2^^7^83^30
 ;;^UTILITY(U,$J,358.3,2682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,2682,1,3,0)
 ;;=3^Candidiasis,Intertriginal
 ;;
 ;;$END ROU IBDEI06T
